Kimera® Labs Receives FDA Phase I/IIa IND Approval For Its MSC Exosomes Human Study

Kimera Labs will recruit COVID-19 patients for the IV administration of its exosome products commencing in June. This Phase I/IIa study will thoroughly investigate the safety and clinical efficacy of its advanced exosome products and technology. The Company anticipates completing its Phase I/IIa trial in a matter of months, and then to seek approval to commence the final Phase 3 study. Kimera's exosomes are produced at its 28,000 state-of-the-art FDA GMP-inspected manufacturing facilities in Miramar, Florida. Kimera Labs has established a clinical and research team to prioritize future IND clinical FDA submissions to leverage the regenerative and anti-inflammatory properties of its exosomes.

Kimera Labs will recruit COVID-19 patients for the IV administration of its exosome products commencing in June. This Phase I/IIa study will thoroughly investigate the safety and clinical efficacy of its advanced exosome products and technology. The Company anticipates completing its Phase I/IIa trial in a matter of months, and then to seek approval to commence the final Phase 3 study. Kimera's exosomes are produced at its 28,000 state-of-the-art FDA GMP-inspected manufacturing facilities in Miramar, Florida. Kimera Labs has established a clinical and research team to prioritize future IND clinical FDA submissions to leverage the regenerative and anti-inflammatory properties of its exosomes.

Logo - https://mma.prnewswire.com/media/1014981/Kimera_Exosomes_Logo_Blue_2Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/kimera-labs-receives-fda-phase-iiia-ind-approval-for-its-msc-exosomes-human-study-301826094.html